The global gene therapy market was valued at USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, growing at a robust compound annual growth rate (CAGR) of 33.6%. In 2019, the United States led the global landscape, accounting for 59.83% of the total market share.
The gene therapy market is emerging as a transformative force in modern medicine, offering innovative treatment options for a wide range of genetic and acquired diseases. By targeting the root cause of disorders at the molecular level, gene therapy holds the potential to provide long-term or even curative outcomes. Advances in genetic engineering, viral vector technology, and delivery systems have significantly accelerated the development of gene therapy products. The market is witnessing growing interest in areas such as oncology, rare genetic disorders, and neuromuscular conditions. As regulatory support strengthens and clinical success stories increase, the gene therapy market is expected to grow steadily, reshaping the future of disease management and personalized healthcare.
Continue reading for more details:
**https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243**
Market Segmentation:
By therapy type, the gene therapy market is segmented into ex vivo and in vivo approaches.
Based on vector type, segmentation includes viral vectors (such as lentivirus and AAV) and non-viral vectors.
According to application, the gene therapy market covers oncology, genetic disorders, cardiovascular diseases, neurological conditions, and ophthalmological indications.
End-user segments in the gene therapy market include hospitals, specialty clinics, academic research institutes, and contract research organizations (CROs).
Another segmentation layer comprises commercial and non-commercialized therapies in the gene therapy market pipeline.
List Of Key Companies Profiled in Gene Therapy Market: